<DOC>
	<DOC>NCT01511510</DOC>
	<brief_summary>This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of ascending doses administered once daily for 14 days in healthy volunteers.</brief_summary>
	<brief_title>Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy male and/or female subjects of nonchild bearing potential Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs) Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease History of seizures or of a condition with risk of seizures Pregnant or nursing females, and females of child bearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>PF-04958242</keyword>
	<keyword>multiple dose</keyword>
	<keyword>safety</keyword>
	<keyword>schizophrenia</keyword>
</DOC>